• 1
    Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64: 146575.
  • 2
    Mueller TI, Leon AC, Keller MB et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 10006.
  • 3
    Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001; 57: 14559.
  • 4
    Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 8515.
  • 5
    Vos T, Haby MM, Barendregt JJ et al. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61: 1097103.
  • 6
    Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003; 64 (Suppl. 15): 137.
  • 7
    Solomon DA, Keller MB, Leon AC et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 22933.
  • 8
    Kamlet MS, Paul N, Greenhouse J et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995; 16: 1740.
  • 9
    Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 65361.
  • 10
    Sobocki P, Ekman M, Ågren H et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006; 60: 7918.
  • 11
    Sobocki P, Ekman M, Ågren H et al. Resource-use and costs associated with patients treated for depression in primary care. Eur J Health Econ 2007; 8: 6776.
  • 12
    Keller M, Yan B, Dunner D et al. Recurrence prevention: Efficacy of Two Years of Maintenance Treatment with Venxalafine XR in Patients with Recurrent Unipolar Major Depression. Toronto, ON: American Psychiatric Association Meeting, 20–25 May 2006.
  • 13
    Sobocki P, Ekman M, Ågren H et al. Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 2006; 22: 46977.
  • 14
    Machado M, Iskedjian M, Ruiz I et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006; 22: 182537.
  • 15
    Sobocki P, Ekman M, Ågren H et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007; 10: 15360.
  • 16
    Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 62135.
  • 17
    SCB. Statistical Year Book of Sweden. Stockholm: SCB, 2006.
  • 18
    Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 20528.
  • 19
    Angst J, Gamma A, Sellaro R et al. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003; 253: 23640.
  • 20
    Kessing LV, Andersen PK. The effect of episodes on recurrence in affective disorder: a case register study. J Affect Disord 1999; 53: 22531.
  • 21
    General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm, 2003.
  • 22
    Briggs A, Gray A. Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 1999; 3: 3560.
  • 23
    Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 32740.
  • 24
    Stewart WF, Ricci JA, Chee E et al. Cost of lost productive work time among US workers with depression. JAMA 2003; 289: 313544.
  • 25
    Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 51828.
  • 26
    Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ 1998; 7 (Suppl. 1): S7992.
  • 27
    Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960–2000. N Engl J Med 2006; 355: 9207.
  • 28
    King JT Jr, Tsevat J, Lave JR et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Mak 2005; 25: 66777.
  • 29
    Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Läkartidningen 2003; 100: 34367.
  • 30
    Han D, Wang EC. Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics 2005; 23: 56781.
  • 31
    Simon GE, Revicki D, Heiligenstein J et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 15362.
  • 32
    Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001; 46 (Suppl. 1): 21S8S.
  • 33
    American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157: 145.
  • 34
    Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000; 14: 320.
  • 35
    AHCPR. Treatment of Major Depression. AHCPR 93-0551, Vol. 2, No. 5. Rockeville, MD: Agency for Healthcare Policy and Research, 1993.
  • 36
    The Swedish Council on Technology Assessment in Health Care (SBU). Behandling av depressionssjukdomar – En systematisk litteraturöversikt (Treatment of depression). SBU report No 166/3. Stockholm: The Swedish Council on Technology Assessment in Health Care (SBU), 2004.
  • 37
    Hjalte K, Hjelmgren J, Johansson F et al. Betalningsviljan för ett kvalitetsjusterat levnadsår – en pilotstudie. Institutet för Hälsoekonomi. (accessed April 2005).
  • 38
    Dardennes RM, Lafuma A, Fagnani F et al. Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder. Value Health 2000; 3: 407.
  • 39
    Nuijten M, Hadjadjeba L, Evans C et al. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998; 14: 43345.
  • 40
    Nuijten MJ. Assessment of clinical guidelines for continuation treatment in major depression. Value Health 2001; 4: 28194.